The Schick Shadel method is an inpatient treatment for alcohol use disorder that uses chemical aversion therapy to make patients physically repulsed by alcohol. Developed at Schick Shadel Hospital in Seattle, the approach pairs the sight, smell, and taste of a patient’s preferred alcoholic drinks with a drug that triggers intense nausea and vomiting. The goal is not willpower or insight but a deeply conditioned gut reaction: after several sessions, the body responds to alcohol the way it would respond to spoiled food. The treatment is unusual in the addiction field, generating both striking outcome numbers and persistent controversy about whether inducing vomiting counts as humane medicine.
What Actually Happens During Treatment
Patients typically undergo a roughly 10-day inpatient stay. Before each aversion session, they receive an emetic drug, most commonly emetine, sometimes paired with other agents. Once nausea begins building, patients are presented with their preferred alcoholic beverages and asked to smell, swish, and swallow them. The timing is deliberate: the alcohol needs to arrive in the mouth and nose just as the drug-induced sickness peaks, so the brain ties the two experiences together as tightly as possible. A study of 82 hospitalized patients going through this protocol found that after the treatment interval, their positive expectations about drinking dropped significantly, and their confidence in being able to avoid alcohol in high-risk situations increased.1PubMed. Pharmacological aversion treatment of alcohol dependence. I. Production and prediction of conditioned alcohol aversion
The sessions are repeated multiple times over the hospital stay, usually five or more. Each round reinforces the association between alcohol and sickness. Some versions of the protocol also include “reinforcement” sessions after discharge, where the patient returns months later for a booster treatment designed to keep the conditioned aversion fresh. The experience is, by all accounts, unpleasant in the extreme. That is the point. The treatment works by exploiting a survival mechanism that exists in nearly every animal species.
The Biology Behind Conditioned Taste Aversion
Conditioned taste aversion is one of the most robust forms of learning in the animal kingdom. If you eat something and then become violently ill, your brain flags that food as dangerous, often after a single pairing. This response is thought to have evolved to protect animals from poisonous plants and spoiled meat. The Schick Shadel method essentially hijacks this ancient system and redirects it at alcohol.
Research on the emetic drug emetine has shown that it activates specific brain regions involved in nausea and vomiting, particularly the area postrema and the nucleus of the solitary tract. These structures sit at the base of the brain and act as a kind of toxin-detection system, monitoring the bloodstream for substances that signal poisoning. Emetine triggers strong neuronal activation in both areas in a dose-dependent fashion, meaning higher doses produce more intense responses.2PubMed. Involvement of the area postrema and the nucleus tractus solitarius in the emetogenic action of emetine in rats
What makes this relevant to alcohol treatment specifically is that the conditioned response appears to extend beyond simple nausea. Researchers have found that conditioned taste aversion involves a learned reduction in palatability: the substance doesn’t just make you feel sick, it actually starts tasting bad. Animal studies have shown that drugs of abuse, at doses that animals would normally choose to self-administer, can produce this palatability downshift when paired with illness.3PubMed Central. Conditioned taste aversion, drugs of abuse and palatability For alcohol patients, this means the beer or whiskey they used to enjoy doesn’t just trigger anxiety about getting sick; it genuinely starts to taste and smell revolting to them.
Early experimental work provided the first direct evidence that aversion conditioning produces a measurable conditioned response to the taste and smell of alcohol in human patients, not merely a cognitive association or a reported preference change but a physiological reaction.4Behaviour Research and Therapy. Taste aversion therapy with alcoholics: Techniques and evidence of a conditioned response
What Brain Imaging Shows
More recent work using brain scans has started to clarify what changes in the brain after aversion therapy. An fMRI study of patients who underwent chemical aversion therapy found that, compared to their pre-treatment scans, patients showed reduced brain activity in response to alcohol-related cues after treatment. Specifically, activity in the occipital cortex dropped when patients were shown images of alcohol. Patients also reported lower subjective craving.5PubMed Central. The Neurobiological Mechanism of Chemical Aversion (Emetic) Therapy for Alcohol Use Disorder: An fMRI Study
This matters because one of the longstanding criticisms of aversion therapy was that it might only produce surface-level behavioral suppression, the kind of learned avoidance you can override once the memory of getting sick fades. The brain imaging data suggests something deeper is happening. The alcohol cues that would normally light up reward and attention circuits are being dampened at a neurological level, not just overridden by willpower. This does not prove the effect lasts forever, but it does suggest the conditioning reaches beyond conscious decision-making.
Published Outcome Numbers
The outcome data from Schick Shadel’s multimodal inpatient program are, at face value, surprisingly strong for the addiction treatment field, where relapse rates are notoriously high. In a study of 600 chemically dependent patients treated in the program, an independent research organization was able to reach about 71% of them for follow-up. Among those contacted, roughly 65% reported total abstinence from alcohol at one year, and about 60% remained abstinent at a mean follow-up of nearly 15 months. Patients who were also treated for cocaine dependence did even better: over 80% of those contacted reported abstinence from cocaine at one year.6PubMed. Treatment outcome of 600 chemically dependent patients treated in a multimodal inpatient program including aversion therapy and pentothal interviews
A matched comparison study pitted 249 aversion-therapy patients against patients from a national treatment outcome registry who had received standard inpatient treatment emphasizing individual and group counseling without aversion therapy. The groups were matched on 17 baseline variables to make the comparison as fair as possible without a randomized trial. Patients in the aversion therapy group had significantly higher alcohol abstinence rates at both six and 12 months.7Alcoholism: Clinical and Experimental Research. Six‐ and Twelve‐Month Abstinence Rates in Inpatient Alcoholics Treated with Aversion Therapy Compared with Matched Inpatients from a Treatment Registry
These are observational and quasi-experimental findings, not results from randomized controlled trials, and the distinction matters. Patients who choose an aversion therapy program may differ in important ways from patients who enter standard treatment, even after statistical matching. They tend to be more motivated, more financially stable (since the program is expensive and often not fully covered by insurance), and more likely to have intact social support. Still, the size of the differences, particularly among certain subgroups, is hard to dismiss entirely as selection bias.
Who Responds Best
The matched comparison study revealed some interesting patterns in who benefited most from the aversion approach. The largest differences in six-month alcohol abstinence rates between the aversion therapy group and the standard-treatment comparison group appeared among men, patients over 35, daily drinkers, and those whose alcohol use had caused problems at work.8Alcoholism: Clinical and Experimental Research. Six‐ and Twelve‐Month Abstinence Rates in Inpatient Alcoholics Treated with Aversion Therapy Compared with Matched Inpatients from a Treatment Registry All of those subgroup differences were statistically strong.
This pattern makes some intuitive sense. People who drink daily have more entrenched behavioral routines around alcohol, and a visceral physiological aversion may disrupt those routines more powerfully than talk therapy alone. The age finding may reflect that older patients have had more years of failed attempts at moderation, making them readier for an approach that doesn’t ask them to white-knuckle through cravings but instead rewires the craving itself. The work-performance finding could point to a group that has high external motivation to stay sober: their livelihood depends on it.
By 12 months, the abstinence advantage for aversion-therapy patients from all mood-altering substances narrowed and was no longer statistically significant, though the advantage for alcohol specifically remained. This suggests the conditioned aversion may weaken over time without reinforcement, which is consistent with the basic science: conditioned responses do extinguish gradually if they are not periodically renewed. This is likely why the program encourages return visits for booster sessions.
Chemical Versus Electrical Aversion
Not all aversion therapy uses emetic drugs. An alternative approach substitutes mild electric shocks for the nausea-inducing medication. The shocks are applied to the hand or forearm at the moment the patient takes a sip of alcohol. This version avoids the medical risks of emetic drugs and is less physically grueling, but the question has always been whether it works as well.
Research comparing the two approaches has generally found similar abstinence outcomes. A study that separately analyzed faradic (electrical) aversion and chemical aversion groups found no significant differences in abstinence rates, and the electrical aversion group actually showed a slight, nonsignificant edge.9PubMed. Six- and twelve-month abstinence rates in inpatient alcoholics treated with either faradic aversion or chemical aversion compared with matched inpatients from a treatment registry A separate comparison likewise found that patients receiving either chemical or electrical aversion reported similar rates of abstinence at follow-up.10PubMed. A comparison of two aversion treatment methods for alcoholism
These findings are somewhat surprising from a biological standpoint. Conditioned taste aversion in animal research is dramatically stronger when the illness is gastrointestinal rather than, say, a painful shock; the nausea pathway has a privileged connection to flavor learning. That the outcomes look similar in clinical practice may reflect the fact that both approaches are embedded in broader multimodal programs that include counseling, education, and aftercare planning. The aversion component provides the initial disruption of the drinking impulse, but the rest of the program does much of the long-term maintenance work.
Safety and Side Effects
The emetic drugs used in chemical aversion therapy are genuinely potent, and their safety profile has been a recurring concern. Emetine, in particular, has known cardiac risks when used at high doses or over extended periods. Research in animal models investigated whether chronic emetine administration damages heart function by directly harming the mitochondria in heart cells. The findings suggested that the reduction in heart mitochondrial activity seen in emetine-treated animals was caused not by the drug itself attacking the heart but by the general nutritional depletion (inanition) that comes from repeated intense vomiting and loss of appetite.11PubMed. Effects of chronic emetine treatment on mitochondrial function
That distinction matters clinically. It means the cardiac risk is manageable through proper medical supervision, nutritional support, and dose control, rather than being an unavoidable consequence of the drug’s mechanism. In practice, patients undergoing chemical aversion therapy at Schick Shadel are medically monitored throughout, with cardiac screening before admission and close observation during sessions. Patients with certain pre-existing heart conditions or other medical vulnerabilities are typically excluded from the chemical protocol.
Beyond cardiac concerns, the treatment itself is physically taxing. Repeated sessions of induced vomiting can lead to electrolyte imbalances, dehydration, throat irritation, and general exhaustion. These effects are transient and manageable in a hospital setting, but they are real, and they contribute to the treatment’s reputation as extreme. A review of the criticisms leveled at chemical aversion therapy concluded that the available evidence supports both the efficacy and the safety of the approach, provided it is conducted under appropriate medical oversight, though the review acknowledged that the treatment’s aversive nature raises legitimate ethical questions that go beyond pure safety data.12PubMed. Chemical aversion treatment of alcohol dependence. I. Validity of current criticisms
The Ethics Question
The ethical debate around aversion therapy has a complicated history. The technique has been used, sometimes coercively, in contexts that have nothing to do with alcohol, including attempts to change sexual orientation, which were widely condemned and are now considered harmful and scientifically baseless. That historical baggage has colored perceptions of aversion therapy more broadly, making some clinicians reluctant to use or refer patients to the approach even when the target behavior is substance abuse and the patient is participating voluntarily.
The ethical case for aversion therapy in addiction treatment is straightforward in principle: alcoholism kills, conventional treatments have high relapse rates, and patients who freely choose this option after informed consent are exercising autonomy over their own medical care. A review of the ethical and safety considerations around aversion therapy argued that the approach is appropriate in limited circumstances, provided strict controls are maintained over the decision-making process, including confirmation that patients are fully informed and that alternatives have been presented.13Australian & New Zealand Journal of Criminology. Aversion Therapy: Technical, Ethical, and Safety Issues
In practice, the voluntary nature of the treatment at Schick Shadel is an important distinction. Patients typically seek out the program on their own, often after years of failed attempts with other approaches. They are not court-ordered into it, and they can leave at any time. The cost also functions as a self-selection mechanism: the program is expensive, often running into the tens of thousands of dollars, which means patients tend to be highly motivated and personally invested in the process.
Why Most Treatment Centers Don’t Offer It
Despite outcome numbers that compare favorably to almost any other addiction treatment modality, aversion therapy remains a niche offering in the addiction treatment landscape. Most treatment centers in the United States rely on some combination of 12-step facilitation, cognitive behavioral therapy, motivational interviewing, and medication-assisted treatment with drugs like naltrexone or acamprosate. Chemical aversion therapy is offered at only a handful of facilities nationwide.
Several factors explain this scarcity. The treatment requires specialized medical infrastructure, including nursing staff trained in managing emetic protocols, cardiac monitoring equipment, and physicians comfortable prescribing and supervising a procedure that deliberately makes patients severely ill. Standard outpatient or even inpatient addiction programs are not set up for this. The cost of building and maintaining that infrastructure is high, and insurance reimbursement for aversion therapy is inconsistent.
There is also a philosophical mismatch with the direction the field has moved. Modern addiction medicine has shifted toward harm reduction, patient-centered care, and pharmacological approaches that reduce cravings without causing distress. Aversion therapy sits uneasily in that framework: it is the opposite of harm reduction in the short term, even if its long-term aim is total abstinence. Many clinicians trained in the last few decades have never been exposed to it during their education and may not consider it a viable option.
The lack of randomized controlled trials is another barrier. While the observational and quasi-experimental data are encouraging, the evidence base does not meet the standard that guideline committees typically require to issue strong recommendations. Running a randomized trial of aversion therapy would be ethically and practically complicated: you would need patients willing to be randomly assigned to a treatment that involves induced vomiting, and you would need a credible placebo condition for a procedure that cannot easily be blinded.
What the Program Includes Beyond Aversion Sessions
It is worth noting that Schick Shadel’s program is not just repeated vomiting sessions. The hospital uses a multimodal approach that wraps the aversion therapy in a broader treatment package. This includes counseling, education about addiction, relapse prevention planning, and in some cases other procedures. The 600-patient outcome study, for instance, described a program that included both aversion therapy and pentothal interviews, a now-unusual technique in which patients are given a sedative to facilitate deeper psychological exploration.14PubMed. Treatment outcome of 600 chemically dependent patients treated in a multimodal inpatient program including aversion therapy and pentothal interviews
This makes it difficult to isolate exactly how much of the program’s success comes from the aversion component specifically versus the overall intensive inpatient experience. A patient who spends 10 days in a structured, medically supervised environment with daily therapeutic contact is getting something different from a patient who attends outpatient group therapy twice a week, regardless of whether aversion sessions are involved. The matched comparison study attempted to address this by comparing against other inpatient programs, and still found an advantage for the aversion group, but the possibility of unmeasured confounders remains.
Conditioned Aversion and Everyday Experience
If you’ve ever gotten food poisoning from a particular restaurant and found that you couldn’t bring yourself to eat there again, even years later, you’ve experienced a mild version of what aversion therapy tries to create. That spontaneous form of conditioned taste aversion is remarkably persistent. Many people can name a specific food or drink they still cannot stomach because of one bad experience decades ago. The strength and durability of this natural response is exactly what the Schick Shadel method tries to harness.
The difference, of course, is that natural food aversions typically form after genuine poisoning, where the body has a real reason to flag the substance as dangerous. In aversion therapy, the sickness is artificially induced, and the brain is essentially being tricked into treating alcohol as a toxin. Whether this artificial version of the response is as durable as the natural one is an open question. The clinical data showing some erosion of benefit between six and 12 months suggests it may not be, at least not without booster sessions. But the fact that it works at all in the short to medium term speaks to how powerful the underlying biological mechanism is. The brain’s toxin-detection system doesn’t particularly care whether the nausea was “real” or manufactured; what it cares about is the temporal link between the taste and the sickness.